Chimeric antigen receptor (CAR)-modified T-cells targeting CD19 represent a promising therapy for relapsed or refractory (r/r) lymphoma and leukemia. The most common adverse events are immune related and include cytokine release syndrome and neurotoxicity. However. early and late hematological toxicity has emerged as a substantial clinical hurdle leading among others to an increased r... https://danddcollectiblers.shop/product-category/sweets-jar/